Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences reports developments across a commercial portfolio of non-opioid pain management and regenerative health products. Its recurring updates center on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA® extended-release intra-articular corticosteroid injection for osteoarthritis, and the iovera° cold-therapy device for targeted nerve pain control.
Company news also covers earnings and product revenue trends, real-world evidence on opioid use and healthcare costs, pipeline development involving ZILRETTA, iovera° and PCRX-201, share repurchases, equity inducement awards, and stockholder governance matters tied to board composition and proxy materials.
Pacira BioSciences (Nasdaq: PCRX) has announced its acquisition of Flexion Therapeutics for $8.50 per share in cash, plus a contingent value right (CVR) worth up to $8.00 per share, subject to certain milestones. This acquisition adds ZILRETTA, a non-opioid therapy for osteoarthritis knee pain, to Pacira's portfolio, enhancing its commitment to non-opioid pain management. The deal is expected to be accretive to earnings in 2022 and provides significant synergies. Pacira plans to fund the transaction from existing cash resources and expects it to close in Q4 2021, pending regulatory approvals.
TAMPA, Fla., Oct. 08, 2021 – Pacira BioSciences (NASDAQ: PCRX) announces an Investor Day on October 15, 2021, from 8:00 AM to 12:00 PM ET, at its Innovation and Training Center in Tampa. Key Opinion Leaders and the executive team will discuss updates on the company's commercial products and pipeline opportunities. Attendance is limited and requires advance registration. A live webcast and archived replay will be available on PaciraInvestorDay.com.
Pacira BioSciences, Inc. (Nasdaq: PCRX) has received a Paragraph IV Certification Notice Letter from eVenus Pharmaceutical Laboratories regarding a generic version of EXPAREL (bupivacaine liposome injectable suspension). eVenus alleges the corresponding patent is invalid. Pacira is poised to defend its patent rights and has 45 days to initiate a lawsuit. The company possesses additional patents set to extend EXPAREL's market exclusivity into the 2040s, contributing to its competitive position in non-opioid pain management.
Pacira BioSciences, Inc. (Nasdaq: PCRX) has successfully completed process validation for its EXPAREL product, marking a key milestone in increasing its manufacturing capacity. The new 200-liter production suite in Swindon, England, developed in partnership with Thermo Fisher Scientific, is operational, with sales expected to begin by year-end 2021. This expansion aims to achieve gross margins exceeding 85 percent by 2024. Additionally, a new Orange Book-listed patent extends EXPAREL's market exclusivity to January 2041.
ImmuneID, Inc. has appointed James S. Scibetta as the new CEO, succeeding David Donabedian, who will move to an advisory role. Scibetta, with over 20 years of biotech experience, previously led Maverick Therapeutics, acquired by Takeda in April 2021, and held executive roles at Pacira Pharmaceuticals and Bioenvision. Under Donabedian's leadership, ImmuneID raised over $70 million since its launch in Q4 2020. The company focuses on precision immunology, leveraging a proprietary platform for targeting immune diseases.
Pacira BioSciences, Inc. (Nasdaq: PCRX) announced the publication of full results from its Phase 3 PLAY study of EXPAREL in the Journal of Clinical Anesthesia. The study involved 98 pediatric patients undergoing spinal or cardiac surgeries and demonstrated a favorable safety and pharmacokinetic profile, comparable to traditional bupivacaine. Key findings include no serious adverse events and well-tolerated dosing in all age groups. The results support the FDA approval of EXPAREL for pediatric patients aged 6 and older, reinforcing its role as a non-opioid pain management solution.
Pacira BioSciences (Nasdaq: PCRX) reported a 15% increase in EXPAREL net product sales, totaling $41.4 million for August 2021, up from $36.1 million in the previous year. The utilization of EXPAREL, which has treated over nine million patients, is growing despite challenges in the elective surgery market due to the pandemic. The company maintains a positive outlook, expecting annual growth in the high teens and operating margins exceeding 50%. They continue to provide monthly sales updates amid ongoing uncertainties related to COVID-19.
Pacira BioSciences, Inc. (NASDAQ: PCRX) is set to participate in the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 AM ET. The presentation will be virtual, and investors can access the pre-recorded audio via the company's website. Pacira is recognized for its leadership in non-opioid pain management, particularly through its long-acting local analgesic, EXPAREL®, which launched in April 2012. The company also acquired the iovera°® system in 2019 to enhance its offerings in regenerative health solutions.
Pacira BioSciences reported preliminary net product sales for July 2021, achieving $40.9 million for EXPAREL and $1.0 million for iovera°. Additionally, EXPAREL's average daily sales were 117% of July 2020 levels. This growth is attributed to increasing adoption as a non-opioid analgesic during outpatient surgeries. The company acknowledges ongoing uncertainty in the elective surgery market due to potential COVID-19 variants. Monthly unaudited sales reporting will continue until clearer market visibility is established.
PARSIPPANY, N.J., Aug. 4, 2021 - Pacira BioSciences (NASDAQ: PCRX) will present at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021, at 10:20 AM ET. Interested parties can access the live audio via the company’s website. A replay will be available for two weeks post-event. Pacira is dedicated to non-opioid pain management and regenerative health solutions, highlighted by its long-acting analgesic, EXPAREL, launched in April 2012, and the acquisition of the iovera° system in April 2019.